BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 23121914)

  • 1. The past, present and future of renin-angiotensin aldosterone system inhibition.
    Mentz RJ; Bakris GL; Waeber B; McMurray JJ; Gheorghiade M; Ruilope LM; Maggioni AP; Swedberg K; Piña IL; Fiuzat M; O'Connor CM; Zannad F; Pitt B
    Int J Cardiol; 2013 Sep; 167(5):1677-87. PubMed ID: 23121914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
    Mansur SJ; Hage FG; Oparil S
    Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
    Nussberger J; Bohlender J
    Nat Rev Cardiol; 2013 Apr; 10(4):183-4. PubMed ID: 23478259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
    Pugliese NR; Masi S; Taddei S
    Heart Fail Rev; 2020 Jan; 25(1):31-42. PubMed ID: 31512149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
    Morishita Y; Kusano E
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
    Schleich F; Krzesinski JM; Piérard L; Scheen AJ
    Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists].
    Asmar R; Madonna O; Brisac AM; Benetos A; Laurent S
    Therapie; 1998; 53(3):253-70. PubMed ID: 9773125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should ACE inhibitors and ARBs be used in combination in children?
    Stotter BR; Ferguson MA
    Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.